0.43
+0.014(+3.37%)
Currency In USD
Address
545 Fifth Avenue
New York City, NY 10017
United States of America
Phone
212 220 9226
Sector
Healthcare
Industry
Biotechnology
Employees
35
First IPO Date
May 14, 2019
| Name | Title | Pay | Year Born |
| Mr. Les D. Funtleyder | Interm Chief Executive Officer, Chief Financial Officer, Principal Financial Officer & Director | 768,846 | 1970 |
| Mr. John H. Johnson | Executive Chairman | 378,840 | 1958 |
| Mr. Corwin Dale Hooks | Chief Commercial Officer | 636,739 | 1967 |
| Dr. Riccardo Perfetti M.D., Ph.D. | Chief Medical Officer | 860,761 | 1960 |
| Mr. Constantine Chinoporos | Chief Operating Officer & Chief Business Officer | 0 | 1966 |
| Dr. Todd F. Baumgartner M.D., M.P.H. | Chief Regulatory Officer | 0 | N/A |
| Ms. Reena Thomas Colacot | Head of Quality | 0 | N/A |
| Ms. Catherine Thorpe | Interim Chief Accounting Officer | 0 | 1964 |
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.